Skip to main content
. 2012 Mar 19;7:183–199. doi: 10.2147/COPD.S29820

Figure 3.

Figure 3

Cost-effectiveness-frontier analysis for ICS-tolerant patients (A) and ICS-intolerant patients (B).

Abbreviations: GBP, British pound; QALY, quality-adjusted life year; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids.